All filters
Slidesets
Tenofovir exposure during pregnancy and postpartum in hepatitis B mono-infected women on TDF monotherapy compared to HIV-infected women on TDF-containing antiretroviral therapy- Tim Cressey, PhD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Intracellular 007-TP Concentrations are Associated with Gradients of Adherence to Ledipasvir/Sofosbuvir- Leah Jimmerson
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
A Pharmacometabolomics Approach for Predicting Tenofovir diphosphate (TFV-DP) Concentrations in Dried Blood Spots (DBS)- Mustafa Ibrahim
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Application of Physiologically based pharmacokinetic (PBPK) Modelling to Drug Development Decisions- Joga Gobburu, PhD, MBA
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Physiologically based pharmacokinetic modeling and simulation in drug product development and review - Xinyuan Zhang, PhD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
How/when will pharmacogenomics translate into improved clinical care?- David Haas, MD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Last advances in HIV pharmacogenomics - Andrea Calcagno, MD, DTM&H
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
SLC22a2 genetic variants and dolutegravir trough concentrations correlate with specific psychiatric symptoms in hiv-positive patients on dolutegravir- Alberto Borghetti
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Age, Inflammation, Blood Brain Barrier Permeability and Single Nucleotide Polymorphisms in Transporters May Influence Cerebrospinal Fluid Antiretrovirals' Concentrations- Andrea Calcagno, MD, DTM&H
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Assessment of maternal and fetal dolutegravir exposure by integrating ex vivo placental perfusion data and physiologically-based pharmacokinetic modeling- Jolien Freriksen
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Does hepatic impairment affect the exposure of monoclonal antibodies? - Qin Sun
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Reduced nevirapine concentrations among HIV-positive women receiving mefloquine for intermittent preventive treatment for malaria control during pregnancy- Haaland
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Elvitegravir pharmacokinetics during Pregnancy and Postpartum- Angela Colbers
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Clinical Pharmacology of Integrase Inhibitors - Giovanni Di Perri, MD, PhD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Clinical case presentation - Marta Boffito, MD, PhD, FRCP
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Pharmacokinetic and virological efficacy of dolutegravir (50 mg BID) containing regimen in association with rifampin in HIV-infected patients using Dried Blood Spot: ANRS-12313 NAMSAL sub-study in Cameroon- Le
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
First report of dolutegravir unbound plasma concentrations during pregnancy in HIV-positive women- Pauline Bollen
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Update on DDI guidelines of the FDA - in vitro- Xinning Yang, PhD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Update on DDI guidelines of the FDA - in vivo- Kellie Reynolds, PharmD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
How to End the Global HCV Epidemic - the role of injectables- David Thomas, MD, PhD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Medication safety issues associated with currently used first-line antiretroviral regimens in Uganda- Kay Seden
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Intraindividual comparison of efavirenz, atazanavir, or ritonavir plasma pharmacokinetics before and during 21-days of vaginally administered hormone contraception- Kimberly Scarsi, PharmD, MS, FCCP
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Rifabutin (RBT) Decreases Cabotegravir (CAB) Exposure following Oral Co-administration- Patel
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Rifabutin PK and Safety among HIV/TB Coinfected Children Receiving Lopinavir- Holly Rawizza
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018